Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00006215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Study identification
- NCT ID
- NCT00006215
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1999 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Dec 19, 2013
Started 1999
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Gould Medical Group | Modesto | California | 95353 | — |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| Veterans Affairs Medical Center - Washington, DC | Washington D.C. | District of Columbia | 20422 | — |
| Georgia Cancer Treatment Center, P.C. | Riverdale | Georgia | 30274 | — |
| Oncology and Hematology Associates | Westwood | Kansas | 66205 | — |
| Veterans Affairs Medical Center - Brooklyn | Brooklyn | New York | 11209 | — |
| Hematology-Oncology Associates of Rockland, P.C. | New City | New York | 10956 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| Community Oncology Group | Independence | Ohio | 44131 | — |
| CCOP - Dayton | Kettering | Ohio | 45429 | — |
| CCOP - Toledo Community Hospital Oncology Program | Toledo | Ohio | 43623-3456 | — |
| Charleston Hematology-Oncology, P.A. | Charleston | South Carolina | 29403 | — |
| Trident Palmetto Hematology/Oncology | North Charleston | South Carolina | 29406 | — |
| Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group | Memphis | Tennessee | 38119 | — |
| Texas Cancer Care | Fort Worth | Texas | 76104 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555-0209 | — |
| Hematology & Oncology Associates of Virginia | Richmond | Virginia | 23226 | — |
| Morgantown Internal Medicine Group | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2013 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00006215 live on ClinicalTrials.gov.